Creative Biosciences, a Guangzhou cancer screening and cancer diagnostic kit maker, raised $45 million from IDG Capital and CDH Investment in a Series B round. Creative will use the funds to market Colosafe, its early diagnostic kits for colon cancer. The test, which was approved by China’s NMPA in late 2018, is based on fecal genetic testing. Creative says Colosafe is priced at less than half the US cost for similar tests, but has a higher detection specificity than its competitors.
Source: China Biotoday
